Background: Most human papillomavirus (HPV)-related cancers are potentially vaccine-preventable. Persons infected with HIV have excess risk of developing HPV-related cancers but are often hyporesponsive to immunization. We hypothesized that in HIV-infected adults the TLR4 agonist-adjuvanted bivalent HPV vaccine would be more immunogenic than the alum-adjuvanted quadrivalent HPV vaccine. Methodology: We performed an investigator-initiated, double-blind, controlled trial randomizing HIV-positive adults to receive either three doses of the bivalent HPV vaccine (Cervarix, GlaxoSmithKline) or the quadrivalent HPV vaccine (Gardasil, Sanofi Pasteur MSD) at 0, 1.5 and 6 months. Immunogenicity and safety were evaluated for up to 12 months. Primary endpoints were serum neutralizing anti-HPV-16 and anti-HPV-18 antibody geometric mean titers (GMTs) at 7 months measured by pseudovirion-based neutralization assay (PBNA). The HPV-DNA status of the participants was determined before and after immunization. Results: Ninety-two participants were included in the study. Anti-HPV-18 GMTs were higher in the bivalent HPV vaccine group compared with the quadrivalent HPV vaccine group at 7 and 12 months, and no significant differences were found in anti-HPV-16 GMTs among vaccine groups. In the bivalent HPV vaccine group, female compared with male participants had higher anti-HPV-16/-18 GMTs . No gender-specific differences in GMTs were found in the quadrivalent HPV vaccine group. Mild injection site reactions were more common in the bivalent HPV vaccine group than in the quadrivalent HPV vaccine group (91.1% vs. 69.6%; P = .02). No serious adverse events occurred. Conclusions: Compared with the quadrivalent HPV vaccine, the bivalent TLR4-adjuvanted HPV vaccine induced superior vaccine responses among HIV-infected women whereas in HIV-infected men the difference in immunogenicity was less pronounced. Both vaccines were well tolerated. Comparative efficacy trials of HPV immunization in HIV-infected individuals are warranted.